http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2162268-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4acae202b6a15394281949545e70d2f6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J1-0096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J21-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J75-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0016 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J75-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 |
| filingDate | 1971-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1973-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2162268-A1 |
| titleOfInvention | 6-alpha, 17-beta-dihydroxy-13-beta-ethyl-17-alpha - -ethynylgona-4,9,11-triene-3-one - with anti oesterogenic anti-lh and |
| abstract | (A) 6 alpha, 17 beta-dihydroxy-13 beta-ethyl-17 alpha-ethynylgona-4,9, 11-triene-3-one (I) (B) Compounds of formulae (II) (III) where in (II) Z = hydroxyimino; X = O or ethylenedioxy; R' and R2 together represent a double bond between C11 and C12; Y' is OH; Y2 is H; or Z is X is ethylenedioxy; Y' is acetoxy; Y2 is H; R' is Br; R2 is H; or R' and R2 together form a double bond between C11 and C12; in (III) Y is X is O or ethylenedioxy; Z' and Z2 are together hydroxyimino; or Y is oxo; X is ethylenedioxy; Z' and Z2 are together hydroxyimino; or Y is X is ethylenedioxy; Z' and Z2 are together hydroxyimino, acetoxyimino, or O; or Z' is alpha-OH and Z2 is H. (I) has antioestrogenic; pituitary inhibitory and anti-LH activity, and may be used in treatment of e.g. acne, seborrhoea and circulatory disorders associated with menopause. (I) and (II) are intermediates for (I). Suitable dose of (I) is 0.1 to 10 mg/day for adjlts in unit doses of 0.1 to 2mg. |
| priorityDate | 1971-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.